<DOC>
	<DOCNO>NCT02923791</DOCNO>
	<brief_summary>This study compare potential immunogenicity two filgrastims , propose biosimilar Filgrastim Hospira ( US ) US-approved Neupogen reference product . Subjects receive dose one two filgrastims injection 5 micrograms/kilogram ( mcg/kg ) . Subjects receive 5 consecutive daily dos Period 1 ( Days 1-5 ) single dose Day 1 Period 2 . Pre-dose serial post-dose assessment immunogenicity conduct two study period . In addition , safety assessment conduct throughout study .</brief_summary>
	<brief_title>A Study Healthy Volunteers Assess Immune Response Multiple Injections Filgrastim Hospira Neupogen Reference Product .</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . 2 . Willing able comply schedule visit , treatment plan , laboratory test , study procedure . 3 . Healthy male female volunteer 18 65 year age ( inclusive ) . 4 . Body mass index ( BMI ) 19 30 kg/m2 , inclusive , body weight &lt; 50 kg &gt; 95 kg . 5 . Subjects abstain use tobacco nicotinecontaining product least 90 day prior dose negative urine screen cotinine Screening . 6 . Agrees abstain alcohol consumption least 48 hour prior Day 1 dose study period throughout 5 day study treatment negative urine screen alcohol Screening . 7 . Female subject nonchildbearing potential must meet least 1 follow criterion : 1 . Achieved postmenopausal status , define follow : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; status confirm serum folliclestimulating hormone ( FSH ) level confirm postmenopausal state ; 2 . Have undergone document hysterectomy and/or bilateral oophorectomy ; 3 . Have medically confirm ovarian failure . All female subject ( include female subject tubal ligation ) consider childbearing potential Subjects follow characteristics/conditions include study : 1 . Investigator site staff member directly involved conduct study family member , site staff member otherwise supervised investigator , subject Pfizer employee , include family member , directly involve conduct study . 2 . Participation study involve investigational drug within 30 day ( determined local requirement ) 5 halflives precede first dose investigational product ( whichever longer ) prior study entry and/or study participation . 3 . Acute chronic medical psychiatric condition include recent ( within past year ) active suicidal ideation behavior laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . 4 . Any active systemic immunologic disease condition , include limit follow general category : cardiovascular/pulmonary , hepatorenal , systemic infection , lactation . 5 . History malignancy current malignancy exception adequately treat squamous basal cell carcinoma skin cervical carcinoma situ within 5 year . 6 . Any disease condition might interfere absorption , distribution , metabolism , excretion study drug would place subject increase risk . 7 . Hematologic laboratory abnormality include leukocytosis ( defined total leukocytes &gt; 11,000/mcL ) , leukopenia ( define total leukocyte &lt; 4000/mcL ) , neutropenia ( define absolute neutrophil count [ ANC ] &lt; 1500/mcL ) , thrombocytopenia ( defined platelet count &lt; 150/mcL ) . 8 . Lacks adequate hepatic reserve define aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥ 1.5 x upper limit normal ( ULN ) reference lab ; lack renal reserve define serum creatinine ≥1.2 x ULN reference lab estimate glomerular filtration rate ( eGFR ) ≤ 80 mg/min ; know history glomerulonephritis . 9 . Clinically significant , judged investigator , vital sign , 12lead electrocardiogram ( ECG ) abnormality . 10 . History biological growth factor exposure , include limited filgrastim GCSFs context treatment , prophylaxis , peripheral blood stem cell mobilization , previous investigational study set . 11 . Receipt live vaccination , exposure communicable viral disease chicken pox , varicella , measles within 4 week prior Screening . 12 . Surgery within 4 month prior Screening . 13 . Use prescription medicine ( exception contraceptive ) within 7 day least 5 halflives , whichever longer . Use oral parenteral anticoagulant antiplatelet agent corticosteroid specifically query . 14 . Administration drug depot injection ( exception depot contraception ) within 30 day prior initial study drug administration 5 halflives drug , whichever longer . 15 . Use counter medication , include aspirin nonsteroidal antiinflammatory drug , natural preparation ( dietary supplement herbal product ) within 7 day least 5 halflives , whichever longer . Vitamins calcium supplement allow ( exceed 100 % daily value ) . 16 . History drug alcohol abuse within 2 year prior randomization , determine investigator positive urine screen drug abuse Screening . Screening drug abuse minimally include cannabinoids , opiate , barbiturate , amphetamine , cocaine , benzodiazepine . 17 . Drug sensitivity , allergic reaction , know hypersensitivity/idiosyncratic reaction E. coliderived protein , filgrastim , pegfilgrastim , GCSFs component product : subject rare heredity problem fructose intolerance exclude due excipient sorbitol . 18 . History splenic rupture ( subject asplenic ) , pulmonary infiltrate pneumonia , sickle cell disorder , chronic neutropenia , thrombocytopenia , vasculitis . 19 . Any clinically significant , determined investigator , abnormal laboratory evaluation , include human immunodeficiency virus antibody ( HIVAb ) , hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) liver function take Screening . Negative HIVAb status confirm Screening result maintain confidentially study site . 20 . Blood donation ( include plasma donation ) approximately 1 pint ( 500 mL ) within 60 day prior dose OR transfusion blood product within 90 day prior Screening . 21 . Pregnant female subject , breastfeed female subject , fertile male subject female subject childbearing potential unwilling unable use least 1 highly effective method contraception outline protocol duration study least 28 day last dose investigational product . 22 . Unwilling unable comply criterion Lifestyle Requirements section protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>